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Background-—Small molecule kinase inhibitors (KIs) are a class of agents currently used for treatment of various cancers.
Unfortunately, treatment of cancer patients with some of the KIs is associated with cardiotoxicity, and there is an unmet need for
methods to predict their cardiotoxicity. Here, we utilized a novel computational method to identify protein kinases crucial for
cardiomyocyte viability.
Methods and Results-—One hundred forty KIs were screened for their toxicity in cultured neonatal cardiomyocytes. The kinase
targets of KIs were determined based on integrated data from binding assays. The key kinases mediating the toxicity of KIs to
cardiomyocytes were identiﬁed by using a novel machine learning method for target deconvolution that combines the information
from the toxicity screen and from the kinase proﬁling assays. The top kinases identiﬁed by the model were phosphoinositide 3-
kinase catalytic subunit alpha, mammalian target of rapamycin, and insulin-like growth factor 1 receptor. Knockdown of the
individual kinases in cardiomyocytes conﬁrmed their role in regulating cardiomyocyte viability.
Conclusions-—Combining the data from analysis of KI toxicity on cardiomyocytes and KI target proﬁling provides a novel method to
predict cardiomyocyte toxicity of KIs. ( J Am Heart Assoc. 2019;8:e013018. DOI: 10.1161/JAHA.119.013018.)
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T reatment of patients with kinase inhibitors (KIs) hasdramatically improved the prognosis of many cancers.
Unfortunately, treatment of patients with some of the KIs is
associated with cardiotoxicity, and has raised concerns for
adverse cardiac effects of kinase inhibition. There are 518
kinases encoded by the kinase genome (kinome).1 In many
cancers, mutations in 1 or several genes encoding kinases
can lead to failure in tumor suppression or overexpression of
proto-oncogenic proteins. Kinase inhibition in cancer cells can
efﬁciently kill it or stop its growth but, unfortunately, many
kinases that drive tumorigenesis are also important for
cardiomyocyte survival and function.2 In addition, most KIs
exhibit poor selectivity in their kinase targets because of high
homology of ATP pockets across the kinases. Because of the
diverse kinase targets found for each KI, many approved KIs
are associated with adverse events including cardiomyopa-
thy.3–5 Currently, among the clinically approved KIs, ponatinib
and vandetanib are labeled with the black box warning for
cardiovascular implications while for pazopanib, sunitinib,
nilotinib, sorafenib, ceritinib, crizotinib, and dasatinib, the
cardiovascular events are listed as possible adverse side
effects.5
Cardiotoxicity has accounted for nearly half of the drug
withdrawals, indicating that the predictive value of currently
available toxicity screening methods is poor.6 Cardiotoxicity
caused by a KI could result from both (1) on-target toxicity
where the kinase that enhances the tumor cell growth is
also important for the cardiomyocyte survival; or (2) off-
target toxicity where a KI leads to toxicity via inhibition of
a kinase not intended to be a target of the drug.2,3 Off-
target toxicity is mainly observed in multitargeted KIs that
interact with a wide array of kinase targets. A growing
number of patients, many of them with cardiovascular
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comorbidities, are receiving treatments with KIs and
currently, predicting cardiotoxicity of KIs in the preclinical
phase is a challenge.
Herein, we carried out a systematic approach for identi-
fying kinases, whose inhibition is detrimental for cardiomy-
ocyte viability. We performed analysis of 140 KIs for their
ability to induce cardiotoxicity in neonatal rat ventricular
cardiomyocytes in vitro. Cardiomyocyte viability was analyzed
by measuring the ATP levels in cardiomyocytes after exposure
of cells to a 3-log concentration range of each KI for 24 hours.
KIs were then analyzed for their kinase targets based on
integrated data from binding assays for wild-type kinases
(418) considering both on- and off-targets of the KIs. Finally,
we developed a novel machine learning method for target
deconvolution that combines the information from our toxicity
screen and from the kinase proﬁling assays to identify kinases
crucial for cardiomyocyte viability.
Methods
Animal handling and cardiomyocyte isolation were carried out
in accordance with University of Oulu institutional guidelines,
which conform to the National Research Council (US) Guide
for the Care and Use of Laboratory Animals. An expanded
methods section is provided in Data S1.
Data Availability
The authors declare that all supporting data are available
within the article and its online supplementary ﬁles.
Predictive Target Deconvolution
We developed and applied a novel probabilistic machine
learning–based predictive target deconvolution approach
(PTD). The key assumption of PTD is that by modeling the
KI response as an outcome of the target binding afﬁnities, one
can deconvolute and identify the key targets that are
responsible for the prediction of the response. Speciﬁcally,
PTD extends sparse linear regression7 to the case where
predictor variables may contain missing values (here, binding
afﬁnities, see below). This is achieved by modeling missing
predictor variables as parameters of the model that are
learned during the inference procedure. As a result, PTD can
be considered as a sparse linear regression for noncomplete
predictor variables. PTD was used to model the dose–
response measurements of a set of KIs as regression
outcomes of the corresponding binding afﬁnities. The model
is formulated in the Bayesian paradigm as:
y Normal ðXb; rÞ
XuNormal ð0; cÞ
b Laplace ðaÞ
r InvGamma ða; bÞ
Here, y forms the dose–response measurements while X
are the binding afﬁnities. The outcome variables y are
regressed from X with regression coefﬁcients b. Xu represent
the unobserved and missing binding afﬁnities. We assume Xu
to be centered around zero to match the background data
distribution. We also assume normal distributions on y and Xu
for simplicity, while varying these could further improve the
results. We assume b to have a Laplace prior inspired from
sparse linear regression7 to induce sparsity for the kinase
feature selection. Finally, the hyperparameters (a=1, c=1) are
also initialized to induce sparsity in both b and Xu to match
the assumption of sparse feature selection in b and sparsely
observed binding afﬁnities in Xu. The noise parameter r is
assumed to have a noninformative symmetric prior with
shape and rate parameters a,b set to 1. The model was
implemented using Gibbs sampling obtaining 200 posterior
samples with a thinning factor of 10 and a burnin of 2000
iterations.
To quantify the KI responses, the dose–response curves
were summarized using the quantitative drug sensitivity score
(DSS).8 The area under the dose–response curve (AUC) was
calculated by ﬁtting a 4-paremeter logistic function to the
normalized %inhibition values over the concentration points. A
predeﬁned noise threshold (10% inhibition) was further used
Clinical Perspective
What Is New?
• We show that a novel computational method can be used to
in vitro screen cardiotoxicity of new kinase inhibitors, a
group of widely used anticancer drugs.
• Our data identify novel kinase inhibitor targets, such as dual
inhibition of phosphoinositide 3-kinase catalytic subunit
alpha and mammalian target of rapamycin, as potential
mediators of cardiomyocyte viability and cardiotoxicity.
What Are the Clinical Implications?
• The clinical relevance of this novel assay was supported by
identiﬁcation of well-known cardiotoxic kinase inhibitors.
• Toxicity of dual phosphoinositide 3-kinase catalytic subunit
alpha/mammalian target of rapamycin inhibition on car-
diomyocytes may bear relevance for future drug design
targeting the phosphoinositide 3-kinase catalytic subunit
alpha/mammalian target of rapamycin pathway.
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in the calculation of the drug sensitivity score (DSS), which
classiﬁes each compound with dose–response curved below
the threshold as inactive (DSS=0). DSS data from 103 KIs
used at maximum 10 lmol/L concentration were used in the
PTD analysis. We used both on- and off-target binding afﬁnity
proﬁles to model the polypharmacological effects of KIs. The
kinase binding afﬁnities of 132 of the 140 compounds were
extracted from the FIMM in-house Drug Target Commons
database.9 For the remaining 8 compounds, the target afﬁnity
data were obtained from Davis et al.10 The integration of the
bioactivity proﬁles was based on the KIBA algorithm.11
Kinases with afﬁnity values indicating low potency
(>1000 nmol/L) were removed as nonrelevant. Further-
more, kinases targeted by ≤3 inhibitors were excluded
since they were considered statistically unreliable for PTD
inference. This resulted in a total of 295 kinases that were
used for modeling the response proﬁles of the 103 KIs
(Data Set 1).
The PTD model was used to infer the top kinases
associated with the DSS toxicity responses, where the PTD
parameters were estimated using leave-one-out cross-valida-
tion. The learned importance scores (regression weights) from
each fold were then averaged over the 103-folds to identify
the kinases that are robustly linked to the toxicity response.
We selected the top-10 kinases based on the regression
weights that were found to be consistent across the cross-
validation folds using t test with Bonferroni multiple-hypoth-
esis correction (differentiating the weights from zero null
hypothesis).
Statistical Analysis
Statistical analysis was performed with GraphPad software.
Normally distributed data were analyzed with t test for 2-
sample comparisons. For analysis of 3 or more groups,
ANOVA followed by Dunnett’s test was used. Differences were
considered statistically signiﬁcant at the level of P<0.05. Data
are shown as meanSD.
Results
Effect of KIs on Cardiomyocyte Viability
Measuring the ATP content in viable cells is a widely used
approach in cytotoxicity screening applications in vitro. In
cardiomyocytes, the number of cells plated showed a linear
relationship and were highly correlated with both the ATP
measured (r2=0.98, Figure S1A) and the amount of total
protein measured at the end of the experiment (r2=0.98,
Figure S1B).
For the toxicity analysis, cells were plated at a density of
60 000 cells/well, which is in the linear range of the ATP
assay (Figure S1A). After exposure of cardiomyocytes to a 3-
log concentration range of each KI for 24 hours, an ATP assay
was performed to determine the number of viable cells in
culture. Eighty-one of 140 KIs tested showed >10% decrease
in cell viability and 27 showed a >30% decrease in cell viability
(Figure 1A). The dose–response curves for 33 clinically
approved KIs included in the screen are shown in Figure 1B.
Twenty-ﬁve of the 33 clinically approved KIs included in the
study demonstrated a moderate-to-high toxicity to cardiomy-
ocytes. Geﬁtinib, bosutinib, regorafenib, ponatinib, and
midostaurin reduced cardiomyocyte viability by >50% at the
maximum concentration tested, while imatinib, erlotinib,
sorafenib, sunitinib, dasatinib, lapatinib, nilotinib, pazopanib,
axitinib, trametinib, afatinib, ibrutinib, idelalisib, nintedainb,
palbociclib, neratinib, binimetinib, dacomitinib, fostamitinib,
and everolimus reduced cardiomyocyte viability by 10% to
50% at the maximum concentration tested. The dose–
response curves for all KIs analyzed are shown in Table S1.
Identiﬁcation of Kinases Necessary for
Cardiomyocyte Survival
The DSS calculation is based on the integration of the area
under the dose–response curve to quantify the summary
response intensity. The DSS score is deﬁned within the range
of 0 to 50, with close to 0 specifying no response, >5
indicating moderate response, and values close to 50
representing maximally toxic response.8 DSS score indicated
moderate-to-high cardiomyocyte toxicity for 35 of the KIs
tested (DSS >5, Figure 2A). Nineteen of the compounds
induced low-to-moderate toxicity on cardiomyocytes
(2<DSS<5, Figure 2B). DSS values for all the KIs tested are
shown in Table S2.
To identify the kinase targets conferring cardiomyocyte
toxicity, we analyzed a subset of 103 KIs that were used at
maximum 10 lmol/L concentration. Thirty of the KIs had
DSS >5 with 10 lmol/L concentration, with expected dose
response with 3 and 1 lmol/L concentrations (Figure 2C). A
linear regression model was then used to infer the kinases
linked with the toxicity response in cardiomyocytes (Fig-
ure 2D, Table). The top kinases identiﬁed by the model were
phosphoinositide 3-kinase catalytic subunit alpha (PI3Ka,
p110a), mammalian target of rapamycin (mTOR), and insulin-
like growth factor 1 receptor (IGF1R). The rank for Mek1 that
has been previously shown to protect the cardiomyocytes
from various stresses was 11 (Table).12 To exclude possible
nonspeciﬁc toxicities of the kinase inhibitors, we next
repeated the PTD model analysis by omitting the toxicity
data with the 10 lmol/L KI concentration. Analysis for
kinases mediating the toxicity with maximum 3 lmol/L
concentration identiﬁed the same top 3 kinases (PI3Ka,
IGF1R, and mTOR) having the highest regression weights
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(Figure 2E). Other kinases identiﬁed by both concentration
thresholds were B-Raf, PI3K catalytic subunit delta
(PI3Kd), RAF proto-oncogene serine/threonine-protein kinase
(Raf-1), PI3K catalytic subunit type 2 beta (PI3K2b), and
mitogen-activated protein kinase kinase kinase 7 (MAP3K7 or
TAK1).
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Figure 1. Toxicity of kinase inhibitors (KIs) on cardiomyocytes. Neonatal rat cardiomyocytes were treated with a 3-log concentration range for
each kinase inhibitor, and cardiomyocyte viability was assessed by ATP assay. A, Classiﬁcation of cardiomyocyte toxicity of 140 KIs according to
percent of viability decreased at maximum concentration. B, Dose–response curves for cardiomyocyte viability (% viable cells) of approved KIs
analyzed. Each point on the curves represents a mean of 2 replicates.
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Several Kinases
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Figure 2. Determination of drug sensitivity score (DSS) and kinases associated with cardiomyocyte survival. A, Kinase inhibitors (KIs) with
moderate to high toxicity (DSS >5) and their primary kinase targets. B, KIs with low-to-moderate toxicity (5>DSS>2) and their primary kinase
targets. C, DSS and the primary kinase targets for KIs tested at 10 lmol/L maximum concentration. Shown are KIs with DSS>5 and the
corresponding DSS value at 3 and 1 lmol/L cutoffs. D, Corresponding regression weights of top 10 kinase targets identiﬁed by using
10 mmol/L maximum concentration. E, Corresponding regression weights of top 10 kinase targets identiﬁed by using 3 mmol/L maximum
concentration. P values are calculated using 1-sided t test.
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Dual Inhibition of PI3Ka and RICTOR Induces
Necrotic Cardiomyocyte Death
mTOR inhibitors analyzed in the study target either mTOR
complex 1 (mTORC1) (everolimus and sirolimus) or both
mTORC1 and mTORC2 (AZD8055, vistusertib, PP242, sapa-
nasertib, and OSI-027), with markedly higher cardiomyocyte
toxicity (DSS >4.3) observed with mTORC1/2 inhibitors. To
further investigate the role of PI3Ka, IGF1R, and mTOR, we
treated cardiomyocytes with KIs targeting either PI3K, IGF1R,
mTOR, or both PI3K and mTOR (dual PI3K/mTOR inhibitors)
and analyzed for both ATP levels and necrotic cardiomyocyte
death. Cardiomyocytes were incubated with 2-log concentra-
tion range of each inhibitor for 24 and 48 hours. Twenty-four-
hour incubation of compounds induced a dose-dependent
decrease in cardiomyocyte ATP levels, while only PI3K and
dual PI3K/mTOR inhibitors induced consistent increase in
necrotic cell death (Figure S2 and Table S3). While treatment
of cardiomyocytes with some inhibitors (pilaralisib, buparlisib,
pictilisib, BMS754807, and omipalisib) induced necrotic cell
death with only modest decrease in ATP levels, our data
suggest that there is a threshold for the decrease in ATP
levels (with 50–60% decrease) that results in necrotic
cardiomyocyte death (adenylate kinase release). Forty-eight-
hour treatment with KIs induced a further decrease in ATP
levels, and cardiomyocyte toxicity was observed even with the
lowest KI concentration (100 nmol/L) with most of the
inhibitors (Figure 3). However, necrotic cell death was
consistently observed with only dual PI3K/mTOR inhibitors.
To conﬁrm the role of the top kinase targets identiﬁed on
regulating cardiomyocyte viability, we used RNAi to downreg-
ulate PI3Ka, IGF1R, and RICTOR (speciﬁc protein subunit in
the mTORC2 complex) in cardiomyocytes. Quantitative poly-
merase chain reaction analysis showed that 70 nmol/L siRNA
was sufﬁcient to decrease the expression levels of the kinases
by 50% (Figure S3). It is of note that the decrease in kinase
levels achieved by the chosen siRNA concentrations was not
complete, but rather mimicked the inhibition achieved with
clinically relevant concentration of KIs. Analysis of cardiomy-
ocyte toxicity by ATP assay indicated that PI3Ka and IGF1R
silencing modestly reduced cardiomyocyte viability, while
RICTOR silencing had no effect (Figure 4A). Interestingly,
combined knockdown of the kinases (PI3Ka+IGF1R, PI3Ka+R-
ICTOR, or IGF1R+RICTOR) resulted in toxicity on cardiomy-
ocytes (Figure 4A). Analysis for adenylate kinase release
showed that knockdown of individual kinases did not induce
necrotic cell death, and only combined silencing of PI3Ka and
RICTOR resulted in an increase in AK release (Figure 4B).
Taken together, inhibition of either PI3Ka or IGF1R induces a
decrease in cellular ATP levels indicative of reduced car-
diomyocyte viability. Dual inhibition of PI3K and mTOR
decreases cellular ATP levels and induces necrotic cardiomy-
ocyte death.
Discussion
Most of the current data concerning the role of protein
kinases in maintenance of normal cardiomyocyte homeostasis
are based on studies in mouse knockout models. However,
predicting the KI toxicity based entirely on ﬁndings in
genetically engineered mice may be misleading. Data from
studies with germline knockout mice could be confounded by
unique developmental roles of the gene. Conditional kinase
knockout in cardiomyocytes, on the other hand, results in
complete and permanent inhibition of a kinase, which is not
achieved with a KI. Knockout models also disrupt protein–
protein interactions that will generally not be disrupted with
Table. Kinases Regulating Cardiomyocyte Survival Identiﬁed
by Predictive Target Deconvolution Model
Rank Targets Regression Weights P Values
1 PI3Ka 1.025 1.68 E-27
2 mTOR 0.697 9.57 E-30
3 IGF1R 0.578 1.86 E-25
4 CHEK2 0.511 0.008
5 PI3KCd 0.364 2.30 E-19
6 PI3Kb 0.356 1.60 E-08
7 Raf-1 0.274 1.55 E-18
8 FLT3 0.242 6.53 E06
9 B-RAF 0.219 6.97 E-18
10 MAP3K7 0.217 1.54 E-06
11 MAP2K1 0.198 2.33 E-05
12 PDGFRA 0.183 1.99 E-12
13 PI3Kc 0.165 5.65 E-21
14 AURKA 0.154 4.57 E-14
15 MET 0.146 2.07 E-06
16 NTRK3 0.142 1.92 E-12
17 MAP4K5 0.126 1.22 E-11
18 CSNK1D 0.125 2.23 E-05
19 FGFR3 0.117 1.82 E-08
20 AKT1 0.108 0.004
21 MST1R 0.100 6.37 E-06
The kinases ranking is based on the regression weights using the data from 103 kinase
inhibitors tested at maximum concentration 10 lmol/L. AKT1 indicates RAC-alpha
serine/threonine-protein kinase; AURKA, aurora kinase A; B-RAF, Serine/threonine-
protein kinase B-raf; CHEK2, check point kinase 2; CSNK1D, casein kinase 1 delta;
FGFR3, ﬁbroblast growth factor receptor 3; FLT3, Fms-related tyrosine kinase 3; IGF1R,
insulin-like growth factor-1 receptor; MAPK, mitogen-activated protein kinase; MET,
Hepatocyte growth factor receptor; MST1R, macrophage stimulating-1 receptor; mTOR,
mammalian target of rapamycin; NTRK3, neurotrophic receptor tyrosine kinase 3;
PDGFRA, platelet-derived growth factor receptor alpha; PI3K, phosphoinositide 3-kinase;
Raf-1, RAF proto-oncogene serine/threonine-protein kinase.
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the drug treatment. This could cause phenotypes in the
knockouts that would not be seen with KI treatment.
Currently, there are 50 KIs approved by the US Food and
Drug Administration and 250 KIs are currently investigated
in clinical trials. However, very few of the KIs target only 1
protein within physiologically relevant concentrations.13,14
The nonclinical development of KIs as well as other anticancer
products are mostly performed in line with the ICHS9
regulatory guideline, which only recommends electrocardio-
graphic measurements and appropriate clinical observation to
monitor cardiovascular safety.15 Thus, there is a high unmet
need for screening methods that would identify cardiovascular
toxicity, and speciﬁcally cardiomyocyte toxicity, in earlier
phases of anticancer drug development. The neonatal
cardiomyocytes provide a unique screening tool to study KI-
mediated cardiotoxicity because of their characteristic per-
sistent rhythmic contraction and thus constant requirement
for high level of ATP production. It has been shown that, using
neonatal cardiomyocytes, many KIs in clinical use including
lapatinib, erlotinib, geﬁtinib, imatinib, sorafenib, sunitinib, and
dasatinib induced cardiomyocyte toxicity in a way that
correlated with the clinical cardiotoxicity data.16,17
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Figure 3. Toxicity of selective PI3K, IGF1R, mTOR, and dual PI3K/mTOR on cardiomyocytes. Neonatal rat
cardiomyocytes were treated with 4 different concentrations of each inhibitor for 48 hours. At the end of
the experiment, medium samples were collected for adenylate kinase (AK) assay and cells were lysed for
measurement of ATP levels. Shown are analyses for cardiomyocyte toxicity by ATP assay (left column) and
AK assay (right column). Data for ATP assay are shown as percent of viable cells and for adenylate kinase as
fold change vs control. Concentrations from left to right are 0.1, 1, 3, and 10 lmol/L. Data are represented
as meanSD **P<0.01; ***P<0.001 (Dunnett’s test).
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Apoptosis, necrosis, and autophagy can all contribute to
cardiomyocyte death induced by toxic stresses, and the
type of cell death following exposure of cardiomyocytes to
a given compound cannot be predicted. Thus, analysis for
the amount of viable cardiomyocytes following exposure of
cardiomyocytes to novel compounds is the most reliable
method to detect toxicity. The technique of measuring ATP
levels in viable cells is highly sensitive, reproducible, and
less vulnerable to false positive results because of the
ﬂuorescence of compounds themselves that is commonly
observed with ﬂuorescence-based cell viability assays.18
We found that the ATP assay provides a linear analysis
method for measuring cardiomyocyte viability and has a
very low threshold for detection of toxicity. Reduction in
cardiomyocyte ATP levels may also be indicative of
mitochondrial damage/dysfunction that is associated with
cardiotoxicity of some KIs.19,20 In the clinical setting, the
decrease in cardiomyocyte ATP levels does not necessarily
culminate in cell death, but may manifest as left
ventricular dysfunction.
Some aspects need to be taken into account when
extrapolating our data from neonatal cardiomyocytes to adult
cardiomyocytes. Glycolysis is a predominant source of
myocardial ATP production in neonatal cardiomyocytes,
whereas the mature heart is mainly aerobic with free fatty
acids as the predominant energy substrate.21 Moreover,
cardiomyocytes have proliferative capacity in the neonatal
heart, whereas the adult cardiomyocyte proliferation is very
limited.22 Neonatal cardiomyocytes are more resistant to
hypoxia23 and there are differences in calcium signaling
between neonatal and adult cardiomyocytes.24 In the context
of cell death, tumor necrosis factor a triggers apoptosis in
adult cardiomyocytes but not in neonatal cardiomyocytes.25
Furthermore, there are some differences in adult and neonatal
cardiomyocyte response to toxic stresses. For example,
doxorubicin induces calpain-mediated necrotic cell death in
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Figure 4. Co-knockdown of PI3Ka and RICTOR induces cardiomyocyte death. Neonatal rat cardiomy-
ocytes were transfected with 70 nmol/L siRNAs targeting PI3Ka, IGF1R, and RICTOR alone, or in
combinations. A, Analysis of cardiomyocyte viability by ATP assay presented as percent of viable cells. B,
Analysis of cardiomyocyte necrosis by adenylate kinase (AK) assay presented as fold change compared with
control. Scatters represent meanSD (n=6–8) **P<0.01; ***P<0.001 (t test). IGF1R indicates insulin-like
growth factor-1 receptor; PI3Ka, phosphoinositide 3-kinase catalytic subunit alpha; RICTOR, Rapamycin-
insensitive companion of mTOR.
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adult cardiomyocytes, whereas neonatal cardiomyocytes
undergo caspase-dependent apoptosis when exposed to
doxorubicin.26,27
In the current study, the dose–response curve for the
toxicity of each inhibitor was summarized using the quanti-
tative DSS, a metric used to determine area under the curve.
Compared with other metrics such as IC50 and EC50, DSS has
the advantage of being robust against sources of technical
variability, because it is based on continuous interpolation and
integration of multiple dose–response relationships in a high-
throughput formulation.8 By combining the data from DSS
determination and KI target proﬁling, we identiﬁed key
kinases necessary for cardiomyocyte viability. Speciﬁcally, a
sparse linear regression was used to infer the kinases linked
to the toxicity responses. The concentrations of KIs tested
reached maximum free concentration of the compounds in
patients.28 To verify the ﬁndings and to exclude possible
nonspeciﬁc toxicity of the KIs, we also calculated the DSS
values for each inhibitor by omitting the highest concentration
for each inhibitor. Both of the analyses indicated that PI3Ka,
IGF1R, and mTOR are the key top KI targets mediating the
toxicity to cardiomyocytes. There are previous data indicating
that cardiomyocyte damage correlates with lack of KI
speciﬁcity.29 Among the studied KIs in clinical use, bosutinib
and ponatinib are least selective,30 and those are also the KIs
with the highest DSS value. However, for KIs in clinical use,
lack of target speciﬁcity did not correlate with their toxicity to
cardiomyocytes (R=0.31; P=0.14). Because cellular ATP levels
may decrease without actual cell death, we assessed for
rupture of the cell membrane, which is considered a hallmark
of necrotic cell death. Our data indicate that only dual
inhibition of PI3Ka and mTOR by a KI or kinase knockdown is
consistently associated with rupture of the cardiomyocyte cell
membrane. The regression analysis also identiﬁed Raf-1 and
B-Raf among the key mediators of cardiomyocyte viability.
Some Raf inhibitors, however, have been shown to paradox-
ically activate the MAPK pathway in cells bearing oncogenic
Ras or elevated upstream receptor signaling.31–33 The data
concerning the role of Raf-1 and B-Raf in regulating
cardiomyocyte viability should therefore be interpreted with
caution.
Insulin-like growth factor I (IGF1), acting through IGF1R, is
one of the key activators of the PI3K pathway, and activation
of the PI3K/Akt pathway has been linked to protection from
ischemic and toxic cardiac injuries.34,35 Previously, pharma-
cological inhibition of PI3Ka has also been shown to abrogate
the protective effects of ischemic preconditioning.36 Mam-
malian target of rapamycin is found in 2 distinct complexes,
mTORC1 and mTORC2. Cardiomyocyte-speciﬁc deletion of
raptor (speciﬁc subunit of mTORC1 complex) disrupted
PI3K
AKT
IGF1R
↓
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IGF1
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mTORC2
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IGF1R
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PI3K
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Figure 5. The schematic presentation for the signaling of the top 3 kinases crucial for cardiomyocyte
survival. IGF1R is upstream of the prosurvival PI3K/Akt signaling pathway. Dual PI3K/mTOR inhibitors
simultaneously inhibit the phosphorylation of Akt and attenuate the prosurvival function of Akt. Akt
indicates PKB, Akt serine/threonine kinase; IGF1, insulin-like growth factor I; IGF1R, insulin-like growth
factor-1 receptor; mTOR, mammalian target of rapamycin; mTORC2, mammalian target of rapamycin
complex 2; PI3K, phosphoinositide 3-kinase.
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cardiac function under normal physiological conditions and
eventually resulted in heart failure in mice.37 Cardiomyocyte-
speciﬁc RICTOR deletion (speciﬁc subunit of mTORC2 com-
plex), on the other hand, reduced cardiomyocyte survival and
accelerated left ventricular dysfunction in mice in a pressure
overload model.38 Moreover, inhibition of mTORC1 by
rapamycin has been shown to protect against cardiac
ischemia/reperfusion injury, while dual mTOR inhibitors
abolished cardioprotection after ischemic precondition-
ing.39,40 While the downstream signaling mechanisms
regulating response are not fully elucidated, inhibition of
mTORC2 (by RICTOR knockdown) has been shown to reduce
Akt phosphorylation, while rapamycin enhances Akt
phosphorylation.38,41
The PI3K/AKT/mTOR pathway is activated at high fre-
quency in human cancers.42–44 Given the fact that inhibiting
mTORC1 by rapamycin and other rapalogs leads to activation
of the PI3K/AKT pathway as a part of its negative feedback
mechanism, much attention has been paid to combining
mTOR and PI3K inhibitors for additional antitumor activity.45
Dual inhibition of PI3K and mTOR in human cancers inhibits
Akt phosphorylation at 2 distinct phosphorylation sites,
resulting in greater antitumor activity.43 Our current data,
however, show that dual inhibition of PI3K and mTOR also
results in reduced cardiomyocyte survival (Figure 5). Inter-
estingly, the potency of the 4 dual PI3K/mTOR inhibitors
against PI3Ka (Data set 1) highly correlated with the observed
DSS value (R=0.82, P=0.14). Development of dual PI3K/
mTOR inhibitors has been hampered by adverse effects of
compounds, including stomatitis, noninfectious pneumonitis,
rash, hyperglycemia, and immunosuppression.46 Currently,
most of the clinical observations of adverse cardiac effects
are limited to trials with everolimus or mTOR inhibitors,47 and
cardiovascular effects of the dual PI3K/mTOR inhibition are
not well known. Several of the clinically used KIs analyzed in
the current study are associated with adverse cardiac effects.
We found that 81% of clinically approved KIs included in the
study induced toxicity to cardiomyocytes. Use of ponatinib,
dasatinib, trametinib, and midostaurin, all highly toxic to
cardiomyocytes in the current study, have been associated
with development of left ventricular dysfunction and conges-
tive heart failure in patients.48–50 Our data from isolated
cardiomyocytes, however, are not able to detect adverse
cardiovascular events stemming from KI toxicity to other
resident cardiac cells (eg, endothelial cells).
In summary, we developed here a novel in vitro cardiotox-
icity screening method that identiﬁes known cardiotoxic
compounds and protective signaling pathways. The method is
also readily applicable to other experimental models to
identify key kinases mediating cell viability or other biological
response. By using this approach, we identify highly adverse
effects of PI3Ka/mTOR dual inhibition on cardiomyocytes
that may have relevance for future drug design targeting the
PI3Ka/mTOR pathway.
Acknowledgments
We thank Marja Arbelius and Kirsi Salo for technical assistance.
Sources of Funding
This work was supported by Academy of Finland grants
131020 and 297094 to Kerkel€a and 268505 to Magga, and
296516 to Khan, and by Finnish Foundation for Cardiovas-
cular Research (to Elmadani, Magga, and Kerkel€a).
Disclosures
None.
References
1. Roskoski R. A historical overview of protein kinases and their targeted small
molecule inhibitors. Pharmacol Res. 2015;100:1–23.
2. Lal H, Kolaja KL, Force T. Cancer genetics and the cardiotoxicity of the
therapeutics. J Am Coll Cardiol. 2013;61:267–274.
3. Force T, Kerkel€a R. Cardiotoxicity of the new cancer therapeutics–mechanisms
of, and approaches to, the problem. Drug Discov Today. 2008;13:778–784.
4. Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and
translation of preclinical models to clinical outcomes. Nat Rev Drug Discov.
2011;10:111–126.
5. Yeh ETH, Chang H-M. Oncocardiology-past, present, and future: a review.
JAMA Cardiol. 2016;1:1066–1072.
6. Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial
dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015;309:
H1453–H1467.
7. Park T, Casella G. The Bayesian lasso. J Am Stat Assoc. 2008;103:681–686.
8. Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R,
Majumder MM, Malani D, Murum€agi A, Knowles J, Porkka K, Heckman C,
Kallioniemi O, Wennerberg K, Aittokallio T. Quantitative scoring of differential
drug sensitivity for individually optimized anticancer therapies. Sci Rep.
2015;4:5193.
9. Tang J, Tanoli Z-R, Ravikumar B, Alam Z, Rebane A, V€ah€a-Koskela M, Peddinti
G, van Adrichem AJ, Wakkinen J, Jaiswal A, Karjalainen E, Gautam P, He L, Parri
E, Khan S, Gupta A, Ali M, Yetukuri L, Gustavsson A-L, Seashore-Ludlow B,
Hersey A, Leach AR, Overington JP, Repasky G, Wennerberg K, Aittokallio T.
Drug target commons: a community effort to build a consensus knowledge
base for drug-target interactions. Cell Chem Biol. 2018;25:224–229.
10. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M,
Treiber DK, Zarrinkar PP. Comprehensive analysis of kinase inhibitor
selectivity. Nat Biotechnol. 2011;29:1046–1051.
11. Tang J, Szwajda A, Shakyawar S, Xu T, Hintsanen P, Wennerberg K, Aittokallio
T. Making sense of large-scale kinase inhibitor bioactivity data sets: a
comparative and integrative analysis. J Chem Inf Model. 2014;54:735–743.
12. Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the
heart: angels versus demons in a heart-breaking tale. Physiol Rev.
2010;90:1507–1546.
13. Bhullar KS, Lagaron NO, McGowan EM, Parmar I, Jha A, Hubbard BP,
Rupasinghe HPV. Kinase-targeted cancer therapies: progress, challenges and
future directions. Mol Cancer. 2018;17:48.
14. Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig P-A, Reinecke M,
Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H,
Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T,
Rueckert L, Becker W, Huenges J, Garz A-K, Gohlke B-O, Zolg DP, Kayser G,
Vooder T, Preissner R, Hahne H, T~onisson N, Kramer K, G€otze K, Bassermann
F, Schlegl J, Ehrlich H-C, Aiche S, Walch A, Greif PA, Schneider S, Felder ER,
Ruland J, Medard G, Jeremias I, Spiekermann K, Kuster B. The target landscape
of clinical kinase drugs. Science. 2017;358:4368.
DOI: 10.1161/JAHA.119.013018 Journal of the American Heart Association 10
Screen for Cardiomyocyte Survival Kinases Elmadani et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on December 18, 2019
15. ICH guideline S9 on nonclinical evaluation for anticancer pharmaceuticals,
CHMP/ICH/646107/08. European Medicines Agency. Available at: http://
www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/
2010/01/WC500043471.pdf. Accessed September 20, 2019.
16. Hasinoff BB. The cardiotoxicity and myocyte damage caused by small
molecule anticancer tyrosine kinase inhibitors is correlated with lack of target
speciﬁcity. Toxicol Appl Pharmacol. 2010;244:190–195.
17. Yang B, Papoian T. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity:
approaches to narrow the gaps between preclinical safety evaluation and
clinical outcome. J Appl Toxicol. 2012;32:945–951.
18. Ediriweera MK, Tennekoon KH, Samarakoon SR. In vitro assays and techniques
utilized in anticancer drug discovery. J Appl Toxicol. 2019;39:38–71.
19. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L,
Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris D, Ismail
NS, Chen J-H, Schoen FJ. Cardiotoxicity associated with the tyrosine kinase
inhibitor sunitinib. Lancet. 2007;370:2011.
20. Kerkel€a R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B,
Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA,
Alroy J, Durand J-B, Force T. Cardiotoxicity of the cancer therapeutic agent
imatinib mesylate. Nat Med. 2006;12:908–916.
21. Lopaschuk GD, Spafford MA, Marsh DR. Glycolysis is predominant source of
myocardial ATP production immediately after birth. Am J Physiol. 1991;261:
H1698–H1705.
22. Yutzey KE. Cardiomyocyte proliferation. Circ Res. 2017;120:627–629.
23. Kang PM, Haunstetter A, Aoki H, Usheva A, Izumo S. Morphological and
molecular characterization of adult cardiomyocyte apoptosis during hypoxia
and reoxygenation. Circ Res. 2000;87:118–125.
24. Poindexter BJ, Smith JR, Buja LM, Bick RJ. Calcium signaling mechanisms in
dedifferentiated cardiac myocytes: comparison with neonatal and adult
cardiomyocytes. Cell Calcium. 2001;30:373–382.
25. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL,
Glembotski CC, Quintana PJ, Sabbadini RA. Tumor necrosis factor
alpha-induced apoptosis in cardiac myocytes. Involvement of the sphin-
golipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854–
2865.
26. Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, Suter
TM, Liao R, Sawyer DB. Anthracyclines induce calpain-dependent titin
proteolysis and necrosis in cardiomyocytes. J Biol Chem. 2004;279:8290–
8299.
27. Konorev EA, Vanamala S, Kalyanaraman B. Differences in doxorubicin-induced
apoptotic signaling in adult and immature cardiomyocytes. Free Radic Biol
Med. 2008;45:1723–1728.
28. Liston DR, Davis M. Clinically relevant concentrations of anticancer drugs: a
guide for nonclinical studies. Clin Cancer Res. 2017;23:3489–3498.
29. Hasinoff BB, Patel D. The lack of target speciﬁcity of small molecule anticancer
kinase inhibitors is correlated with their ability to damage myocytes in vitro.
Toxicol Appl Pharmacol. 2010;249:132–139.
30. Uitdehaag JCM, de Roos JADM, van Doornmalen AM, Prinsen MBW, de Man J,
Tanizawa Y, Kawase Y, Yoshino K, Buijsman RC, Zaman GJR. Comparison of the
cancer gene targeting and biochemical selectivities of all targeted kinase
inhibitors approved for clinical use. PLoS One. 2014;9:e92146.
31. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R,
Ludlam MJC, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris
S, Hoeﬂich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS,
Malek S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway
and enhance growth. Nature. 2010;464:431–435.
32. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N,
Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R. Kinase-dead BRAF
and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell.
2010;140:209–221.
33. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors
transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Nature. 2010;464:427–430.
34. Riehle C, Abel ED. Insulin signaling and heart failure. Circ Res.
2016;118:1151–1169.
35. Rossello X, Yellon DM. The RISK pathway and beyond. Basic Res Cardiol.
2017;113:2.
36. Rossello X, Riquelme JA, He Z, Taferner S, Vanhaesebroeck B, Davidson SM,
Yellon DM. The role of PI3Ka isoform in cardioprotection. Basic Res Cardiol.
2017;112:66.
37. Shende P, Plaisance I, Morandi C, Pellieux C, Berthonneche C, Zorzato F,
Krishnan J, Lerch R, Hall MN, R€uegg MA, Pedrazzini T, Brink M. Cardiac raptor
ablation impairs adaptive hypertrophy, alters metabolic gene expression, and
causes heart failure in mice. Circulation. 2011;123:1073–1082.
38. Shende P, Xu L, Morandi C, Pentassuglia L, Heim P, Lebboukh S, Berthonneche
C, Pedrazzini T, Kaufmann BA, Hall MN, R€uegg MA, Brink M. Cardiac mTOR
complex 2 preserves ventricular function in pressure-overload hypertrophy.
Cardiovasc Res. 2016;109:103–114.
39. Sciarretta S, Forte M, Frati G, Sadoshima J. New insights into the role of mTOR
signaling in the cardiovascular system. Circ Res. 2018;122:489–505.
40. Yano T, Ferlito M, Aponte A, Kuno A, Miura T, Murphy E, Steenbergen C. Pivotal
role of mTORC2 and involvement of ribosomal protein S6 in cardioprotective
signaling. Circ Res. 2014;114:1268–1280.
41. Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun S-Y. Enhancing mammalian target
of rapamycin (mTOR)–targeted cancer therapy by preventing mTOR/raptor
inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res.
2008;68:7409–7418.
42. Lee JJ, Loh K, Yap Y-S. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol
Med. 2015;12:342–354.
43. Stratikopoulos EE, Parsons RE. Molecular pathways: targeting the PI3K
pathway in cancer-BET inhibitors to the rescue. Clin Cancer Res.
2016;22:2605–2610.
44. van der Heijden MS, Bernards R. Inhibition of the PI3K pathway: hope we can
believe in? Clin Cancer Res. 2010;16:3094–3099.
45. Dufour M, Dormond-Meuwly A, Demartines N, Dormond O. Targeting the
mammalian target of rapamycin (mTOR) in cancer therapy: lessons from past
and future perspectives. Cancers (Basel). 2011;3:2478–2500.
46. Chia S, Gandhi S, Joy AA, Edwards S, Gorr M, Hopkins S, Kondejewski J, Ayoub
JP, Califaretti N, Rayson D, Dent S. Novel agents and associated toxicities of
inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer.
Curr Oncol. 2015;22:33.
47. Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of
cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma
patients. JACC Heart Fail. 2013;1:72–78.
48. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV,
Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JMG, Utikal J,
Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS,
Ouellet D, Martin A-M, Patel K, Schadendorf D. Improved survival with MEK
inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–114.
49. Pun SC, Neilan TG. Cardiovascular side effects of small molecule therapies for
cancer: table 1. Eur Heart J. 2016;37:2742–2745.
50. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T,
Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M,
Levis M, Cortes J. Phase I/II trial of the combination of midostaurin (PKC412)
and 5-azacytidine for patients with acute myeloid leukemia and myelodys-
plastic syndrome. Am J Hematol. 2015;90:276–281.
DOI: 10.1161/JAHA.119.013018 Journal of the American Heart Association 11
Screen for Cardiomyocyte Survival Kinases Elmadani et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on December 18, 2019
SUPPLEMENTAL MATERIAL
D
ow
nloaded from
 http://ahajournals.org by on December 18, 2019
Supplemental Methods  
Reagents 
A panel of 118 inhibitors was obtained from Institute for Molecular Medicine Finland 
(FIMM). Another panel of 22 inhibitors was purchased from Selleckchem. CellTiter-Glo 
Luminescent Cell Viability Assay was purchased form Promega. The adenylate kinase 
bioassay kit (Toxilight) was purchased from Lonza.  
Isolation of cardiomyocytes 
Collagenase dissociation method was used for isolation of neonatal rat ventricular 
cardiomyocytes. 2-4 days old rat pups were decapitated, the thoracic cavity was opened, 
and the isolated ventricles were perfused with 1% PBS then cut into pieces for digestion in 
collagenase solution (CLS-2 2 g/l and CaCl2 50 μM in PBS) at 37°C.  The cell suspension 
was filtered through 100 μm nylon mesh. To wash collagenase out, the suspension was 
centrifuged for 5 min at 175 g and resuspended in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% FBS and antibiotics (100 IU/ml penicillin and 100 mg/l 
streptomycin). Centrifugation and resuspension were repeated once to enhance washing. 
Pre-plating in 100 mm dishes for 2h at 37°C in humidified air with 5% CO2 was used to get 
rid of non-myocyte cells fraction. The non-attaching cardiomyocytes were collected, and 
viable cells were counted using a Bürker hemocytometer. Cells were plated at a density of 
60000 cells/well using 96 wells plate with clear bottom in 10% FBS DMEM cell culture 
medium for 24h to allow cardiomyocytes to attach after which medium was changed into 
2% FBS Ham’s F10 Nutrient Mix (supplemented with antibiotics) for another 24h before 
experiment started. 
RNA interference 
Specific phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform 
(PI3Kα, p110α), Rapamycin-insensitive companion of mTOR (RICTOR), insulin-like growth 
factor 1 receptor (IGF1R) siRNAs, and negative control siRNA from (ThermoFisher) were 
transfected into the cardiomyocytes using Lipofectamine2000 (Invitrogen) as transfection 
reagent. Cells were incubated in OPTI-mem (Invitrogen) for 18 h, and thereafter the cells 
were incubated in Ham’s F10 Nutrient Mix supplemented with 2% fetal bovine serum. 
RNA analysis 
The RNA was extracted from cardiomyocytes with Trizol reagent following the 
manufacturer’s protocol (Invitrogen, Life Technologies). cDNA was analyzed by 
quantitative real-time polymerase chain reaction (RT-PCR) using the SYBR Green Master 
Mix (ThermoFisher) on an ABI 7300 sequence detection system (Applied biosystems, Life 
Technologies). Oligonucleotide primers used for real time quantitative RT-PCR: PI3Kα 
forward, CACGACCATCTTCGGGTG, and reverse: GGGAGTAAACATTCCACTAGGA; 
Data S1.
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IGF1R forward, GCCCCGATATGCTGTTTG, and reverse: ACTGGGCTCCATCTCATCC; 
RICTOR forward: GACACCATCACCATGAAGG, and reverse: 
ACCATAGACCTAACTGAGGA; 18S forward: CGCCGCTAGAGGTGAAATTC, and 
reverse: CCAGTCGGCATCGTTTATGG.  
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Inhibitor Graph
(5Z)-7-Oxozeaenol (≤10 µM)
Advosertib (MK-1775)  (≤10 µM)
Afatinib (BIBW2992)(≤ 1 µM)
Alisertib (MLN8237) (≤10 µM)
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Table S1. Dose response curves of all KIs included in the screen. 
Quantification of cytotoxicity was done using CellTiterGlo assay after 
treatment of neonatal cardiomyocytes with five different concentrations of 
each kI. Data are mean of two replicates. Inhibitors are shown in alphabetical 
order. Prism (GraphPad) was used for curve fitting.
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Apitolisib (GDC-0980, RG7422)(≤10 µM)
AT9283 (≤1 µM)
Axitinib (≤10 µM)
AZ 3146 (≤10 µM)
AZD1480  (≤10 µM)
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AZD4547 (≤10 µM)
AZD7762 hydrochloride (≤1 µM)
AZD8055  (≤10 µM)
Barasertib (AZD1152-HQPA|AZD2811) (≤1 µM)
BGJ398 (NVP-BGJ398) (≤1 µM)
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BI 2536 (≤1 µM)
Binimetinib (MEK162, ARRY-162, ARRY-438162)(≤ 1 µM)
BMS-754807 (≤10 µM)
BMS-911543 (≤10 µM)
Bosutinib (SKI-606) (≤10 µM)
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Brivanib (BMS-540215)(≤1 µM)
Buparlisib (BKM120, NVP-BKM120) (≤10 µM)
Cabozantinib (XL184, BMS-907351)(≤1 µM)
Canertinib (CI-1033) (≤10 µM)
Cediranib (AZD2171, Recentin) (≤1 µM)
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CP-724714 (≤10 µM)
Crenolanib (CP-868596) (≤10 µM)
Crizotinib (PF-02341066) (≤1 µM)
CUDC-101 (≤10 µM)
Dabrafenib Mesylate (≤ 2,5 µM)
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Dacomitinib (PF299804, PF299)  (≤ 1 µM)
Dactolisib (BEZ235, NVP-BEZ235) (≤10 µM)
Danusertib ( PHA-739358) (≤10 µM)
Dasatinib (≤ 1 µM)
Dinaciclib (SCH727965) (≤1 µM)
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Doramapimod (BIRB 796)  (≤10 µM)
Dovitinib (TKI-258, CHIR-258) (≤10 µM)
Enzastaurin (LY317615)  (≤10 µM)
Erlotinib (≤10 µM)
Everolimus (RAD001)(≤ 1 µM)
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Fasudil (HA-1077) (≤50 µM)
Fedratinib (SAR302503, TG101348) (≤10 µM)
Flavopiridol (Alvocidib) (≤10 µM)
Foretinib (XL880 )(≤10 µM)
Fostamatinib (R935788) (≤2,5 µM)
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Galunisertib (LY2157299) (≤10 µM)
Gandotinib (LY2784544) (≤10 µM)
GDC-0879 (≤10 µM)
Gefitinib (ZD1839)(≤ 10 µM)
Glesatinib (MGCD265) (≤10 µM)
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GSK1838705A (≤10 µM)
GSK2636771 (≤10 µM)
GSK269962 (≤10 µM)
GSK461364A   (≤10 µM)
GSK650394  (≤10 µM)
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GW2580 (≤10 µM)
Ibrutinib (PCI-32765) (≤1 µM)
Idelalisib (CAL-101, GS-1101) (≤10 µM)
Imatinib (STI571)(≤ 10 µM)
Ipatasertib (GDC 0068) (≤ 10 mM)
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KW-2449 (≤10 µM)
KX2-391  (≤10 µM)
Lapatinib (≤ 1 µM)
Lestauritinib (CEP701) (≤1 µM)
Linifanib (ABT-869)  (≤1 µM)
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Linsitinib (OSI-906)(≤10 µM)
Masitinib (AB1010) (≤10 µM)
Midostaurin (PKC412) (≤ 10 µM)
MK-2206  (≤ 1 µM)
MLN-8054  (≤10 µM)
-8 -7 -6 -5
0
5 0
1 0 0
C o n c . L o g  (M )
%
 V
ia
b
le
 c
e
ll
s
-9 -8 -7 -6
0
5 0
1 0 0
C o n c . L o g  (M )
%
 V
ia
b
le
 c
e
ll
s
-8 -7 -6 -5
0
50
100
%
 V
ia
b
le
 c
e
lls
Conc. Log (M)
-8 -7 -6 -5
0
50
100
Conc. Log (M)
%
 V
ia
b
le
 c
e
lls
-8 -7 -6 -5
0
50
100
Conc. Log (M)
%
 V
ia
b
le
 c
e
lls
D
ow
nloaded from
 http://ahajournals.org by on December 18, 2019
Momelotinib (CYT387) (≤10 µM)
Motesanib Diphosphate (AMG-706) (≤50 µM)
Neratinib (HKI-272) (≤ 1 µM)
Nilotinib (AMN-107) (≤10 µM)
Nintedanib (BIBF 1120) (≤ 10 µM)
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Omipalisib (GSK2126458, GSK458)  (≤1 µM)
OSI-027 (≤10 µM)
Palbociclib (PD-0332991) (≤10 µM)
Pazopanib (≤10 µM)
PD 184352 [CI-1040]  (≤10 µM)
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Pelitinib (EKB-569) (≤10 µM)
PF04691502 (≤10 µM)
PF431396 (≤10 µM)
PF4708671 (≤10 µM)
PF477736  (≤10 µM)
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PF4800567 hydrochloride (≤10 µM)
PF670462 (≤10 µM)
PHA-665752 (≤10 µM)
PI 103 (≤10 µM)
Pictilisib (GDC-0941) (≤10 µM)
-8 -7 -6 -5
0
5 0
1 0 0
C o n c . L o g  (M )
%
 V
ia
b
le
 c
e
ll
s
-8 -7 -6 -5
0
50
100
Conc. Log (M)
%
 V
ia
b
le
 c
e
lls
-8 -7 -6 -5
0
50
100
Conc. Log (M)
%
 V
ia
b
le
 c
e
lls
-8 -7 -6 -5
0
50
100
Conc. Log (M)
%
 V
ia
b
le
 c
e
lls
-8 -7 -6 -5
0
50
100
Conc. Log (M)
%
 V
ia
b
le
 c
e
lls
D
ow
nloaded from
 http://ahajournals.org by on December 18, 2019
PIK75 (≤10 µM)
Pilaralisib (XL 147) (≤10 µM)
Pimasertib (AS-703026) (≤10 µM)
PLX-4720 (≤10 µM)
Ponatinib (AP24534) (≤ 10 µM)
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Quizartenib (AC220) (≤ 1 µM)
Rabusertib (LY2603618) (≤1 µM)
RAF265 (CHIR265)(≤10 µM)
Ralimetinib (LY2228820) (≤10 µM)
Rapamycin (Sirolimus) (≤ 1 µM)
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Rebastinib (DCC-2036) (≤1 µM)
Refametinib (RDEA119, Bay 86-9766) (≤10 µM)
Regorafenib (BAY 73-4506) (≤10 µM)
Roscovitine (Seliciclib,CYC202) (≤10 µM)
Ruboxistaurin (LY333531 HCl) (≤10 µM)
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Ruxolitinib (INCB018424,) (≤10 µM)
Sapanisertib (INK128) (MLN0128) (≤ 1 µM)
Saracatinib (AZD0530) (≤10 µM)
Selumetinib (AZD6244)(≤10 µM)
SGX-523 (≤10 µM)
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SNS-032 (BMS-387032) (≤10 µM)
Sonolisib (PX866) (≤10 µM)
Sorafenib (≤ 1 µM)
Sotrastaurin (≤10 µM)
SP600125 (≤10 µM)
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Staurosporine (≤10 µM)
Sunitinib (≤ 1 µM)
TAE-684 (≤10 µM)
TAK-733 (≤10 µM)
TAK901 (≤10 µM)
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Tamatinib (R406) (≤10 µM)
Tandutinib (MLN518) (≤10 µM)
Tepotinib (EMD 1214063) (≤1 µM)
TG-100-115  (≤10 µM)
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Tivantinib (ARQ 197) (≤10 µM)
Tivozanib (AV-951 ) (≤10 µM)
Tofacitinib (CP-690550,Tasocitinib) (≤ 5 µM)
Torkinib (PP242)(≤10 µM)
Tozasertib (VX-680, MK-0457) (≤10 µM)
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Trametinib (GSK1120212) (≤ 0,25 µM)
UCN-01 (≤10 µM)
Vandertanib (≤ 1 µM)
Vatalanib (PTK787) 2HCl (≤10 µM)
Vemurafenib (PLX4032, RG7204)(≤10 µM)
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Vistusertib (AZD2014)  (≤ 2,5 µM)
Volasertib (BI 6727) (≤10 µM)
Voxtalisib (XL765, SAR245409) (≤10 µM)
VX 11E  (≤ 2,5 µM)
VX-745 (≤10 µM)
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ZSTK474  (≤10 µM)
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Kinase Inhibitor DSS Targets Max Conc. Tested 
(nM) 
Staurosporine 44.957 Several Kinases 10000 
UCN-01 36.731 PKCbeta, PDK1, Chk, Cdk2 10000 
PIK-75 25.300 PI3K 10000 
Omipalisib 22.393 PI3K/mTOR 1000 
Midostaurin 20.748 PKC, PKA, S6K and EGFR 10000 
PF-04691502 19.320 PI3K/mTOR 10000 
PI-103 19.210 PI3K 10000 
GSK-1838705A 18.014 IGF1R, INSR, ALK 10000 
BMS-754807 17.531 IGF1R 10000 
Pelitinib 14.488 EGFR 10000 
AZD8055 13.196 mTOR 10000 
TAK-901 12.163 Aurora B 10000 
TAE-684 12.039 ALK, Several Kinases 10000 
CUDC-101 11.558 HDAC & EGFR, Her2 10000 
(5Z)-7-Oxozeaenol 11.492 TAK1 10000 
Apitolisib 10.959 PI3K/mTOR 10000 
Ponatinib 10.717 Broad TK 10000 
Foretinib 10.637 MET, VEGFR2 10000 
Vistusertib (AZD2014) 10.430 mTOR, ATP-competitive 10000 
Buparlisib 9.905 PI3K, pan-class I 10000 
Pictilisib 9.507 PI3K, pan-class I 10000 
Fostamatinib aq 8.839 Syk 2500 
Torkinib (PP-242) 8.831 MTOR 10000 
Volasertib 8.683 PLK1 10000 
Canertinib 8.071 pan-ErbB 10000 
Bosutinib 7.938 Abl, Src 10000 
Sapanisertib (INK128) 6.815 mTOR 1000 
Trametinib 6.636 MEK1/2 250 
TAK-733 6.406 MEK 10000 
Lestaurtinib 6.231 FLT3, JAK2, TrkA, TrkB, TrkC 1000 
SAR302503 5.399 JAK2-selective 10000 
RAF265 5.229 C-Raf 10000 
AZD4547 5.132 FGFR 10000 
Gefitinib 5.096 EGFR 10000 
KW-2449 5.095 AURa AURb FLT3 10000 
Saracatinib 4.928 Src, Abl 10000 
Tozasertib 4.655 pan-Aurora 10000 
Refametinib 4.652 MEK1/2 10000 
KX2-391 4.630 non-ATP competitive Src 10000 
Dasatinib 4.475 BCR/Abl, Src, Kit, EphR 1000 
OSI-027 4.311 mTOR 10000 
Table S2. DSS values, primary kinase targets and maximum concentration tested  of all KIs 
included in the screen. The kinase targets of the compounds were extracted from the FIMM 
in-house Drug Target Commons (DTC) database (https://drugtargetcommons.fimm.fi/). Data 
is arranged in descending order according to DSS vlaues. 
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Linsitinib 4.237 IGF1R, IR 10000 
Regorafenib 4.156 B-Raf, c-Kit, VEGFR2 10000 
Sonolisib 4.051 PI3K, pan-class I, Irreversible 10000 
Ruboxistaurin 3.598 PKCbeta 10000 
Tandutinib 3.560 FLT3, PDGFR, KIT 10000 
Pimasertib 3.438 MEK 10000 
MK-2206 3.428 AKT 1000 
AZD1480 2.808 JAK1/2, FGFR 10000 
GSK-461364 2.728 PLK1 10000 
Nilotinib 2.664 BCR/Abl 10000 
PF 431396 2.657 FAK/PYK2 10000 
MK1775 2.505 Wee1 10000 
Dactolisib 2.169 PI3K/mTOR 1000 
GSK2636771 1.863 p110beta selective PI3K 10000 
Afatinib 1.834 EGFR 1000 
Binimetinib 1.566 MEK 1000 
Selumetinib 1.421 MEK 10000 
Vatalanib 1.318 VEGFR-1 & -2 10000 
GSK269962 1.244 ROCK1 and ROCK2 10000 
Erlotinib 0.896 EGFR 10000 
Pilaralisib 0.860 PI3K,  Pan-class I 10000 
Dacomitinib 0.840 pan-HER 1000 
Gandotinib 0.665 JAK2 10000 
VX-11E 0.653 ERK1 & 2 2500 
Masitinib 0.567 KIT 10000 
Crenolanib 0.555 PDGFRA and PDGFRB 10000 
AZD7762 0.533 Chk1 1000 
Everolimus 0.529 binds FKBP12, mTORC1 100 
PD184352 0.414 MEK1/2 10000 
SP600125 0.389 pan-JNK 10000 
Nintedanib 0.368 VEGFR, PDGFR, FGFR 10000 
GDC-0068 0.353 Akt 10000 
Idelalisib 0.348 PI3K, p110 δ-selective 10000 
PHA-665752 0.331 MET 10000 
PF-670462 0.269 CK1epsilon and CK1delta 10000 
BI 2536 0.233 PLK1 1000 
Sunitinib 0.216 Broad TK 1000 
ZSTK474 0.210 p110gamma selective PI3K 10000 
Voxtalisib 0.153 mTOR/PI3K 10000 
Tamatinib 0.109 Syk 10000 
Axitinib 0.105 VEGFR, PDGFR, KIT 10000 
Danusertib 0.103 Aurora, Ret, TrkA, FGFR-1 10000 
PF-00477736 0.066 Chk1 10000 
Neratinib 0.062 EGFR 1000 
Ibrutinib 0.025 Btk 1000 
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Momelotinib 0.023 JAK1 & 2 10000 
VX 745 0.013 p38MAPK 10000 
MGCD-265 0.009 MET, VEGFR-1, -2, -3, RON, TIE2 10000 
PLX-4720 0.008 BRAF 10000 
Pazopanib 0.002 VEGFR 10000 
Dabrafenib 0 B-Raf(V600E) 2500 
GSK650394 0 SGK1 & 2 10000 
Quizartinib 0 FLT3 1000 
Vemurafenib 0 B-Raf(V600E) 10000 
Tofacitinib 0 JAK3, JAK2(V617F) 5000 
PF-4800567 0 CK1epsilon 10000 
Ralimetinib 0 p38MAPK 10000 
NVP-BGJ398 0 FGFR 1000 
BMS-911543 0 JAK2 10000 
Palbociclib 0 Cdk (Cdk4/6) 10000 
Seliciclib 0 CDK2/7/9 10000 
Doramapimod 0 p38 10000 
Tivantinib 0 MET 10000 
Dinaciclib 0 CDK 1000 
Rebastinib 0 Allosteric ABL, FLT3, TIE2, TRKA 1000 
Alisertib 0 Aurora A 10000 
Motesanib 0 VEGFR, PDGFR, Ret, Kit 10000 
Fasudil 0 Rho kinase, PKA, PKG, PRK, prodrug 50000 
AZD1152-HQPA 0 Aurora B 1000 
Rapamycin 
(Sirolimus) 
0 binds FKBP12, mTORC1 100 
TGX-221 0 p110beta selective PI3K 10000 
Cediranib 0 KDR/Flt/VEGFR 1000 
Vandetanib 0 VEGFR,EGFR, RET 1000 
Cabozantinib 0 VEGFR2, Met, FLT3, Tie2, Kit and 
Ret 
1000 
Rabusertib 0 Chk1 1000 
Sorafenib 0 B-Raf, FGFR-1, VEGFR-2-3, KIT 1000 
Alvocidib 0 Cdk 10000 
MLN-8054 0 AURa AURb FLT3 KIT (PDGFR) 10000 
SNS-032 0 Cdk 10000 
Tivozanib 0 VEGFR1, 2, 3, c-Kit, PDGFRB 10000 
Imatinib 0 Abl, Kit, PDGFRB 10000 
Crizotinib 0 ALK, c-Met 1000 
EMD1214063 0 c-Met 1000 
PF-04708671 0 p70S6K 10000 
GDC-0879 0 BRAF(V600E) 10000 
Ruxolitinib 0 JAK1&2 10000 
Galunisertib 0 TGF-B/Smad 10000 
Dovitinib 0 FGFR 10000 
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CP-724714 0 EGFR ERBB2 10000 
GW-2580 0 CSF1R 10000 
Sotrastaurin 0 PKC 10000 
Enzastaurin 0 PKCbeta 10000 
AT9283 0 Aurora A & B, Jak2, Flt, Abl 1000 
Linifanib 0 VEGFR, PDGFR, CSF-1R, FLT3 1000 
Lapatinib 0 HER2, EGFR 1000 
Brivanib 0 VEGFR 1000 
AZ 3146 0 Mps1 kinase (TTK) 10000 
SGX-523 0 MET 10000 
TG100-115 0 PI3K gamma/delta 10000 
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Inhibitor Max AK release at 
24h 
(folds vs control) 
PI3K mTOR IGF1R 
NVP-AEW541 4.96 (***) • 
Omipalisib/GSK2126458/ GSK458 3.80 (***) • • 
PI-103 2.61 (***) • • 
PKI402 2.09 (***) • • 
BMS754807 1.95 (***) • 
PF04691502 1.76 (***) • • 
PIK75 1.69 (***) • 
Apitolisib 1.69 (***) • • 
BKM120 1.68 (***) • 
GDC0941 1.61 (***) • 
pp242 1.43 (**) • 
XL147 1.37 (***) • 
OSI-027 1.14 (ns) • 
GSK1838705A 1.12 (ns) • 
INK128 1.09 (ns) • 
GSK1904529A 1.02 (ns) • 
Vistusertib 1.01 (ns) • 
AZD8055 1.00 (ns) • 
Lisitinib 1.00 (ns) • 
Table S3. Effect of selective PI3K. IGF1R. mTOR and dual PI3K/mTOR on AK levels at 24h incubation time. 
Neonatal cardiomyocytes were treated with 4 different concentrations of each inhibitor for 24 hours. At the end 
of experiment. media samples were collected for the toxilight assay. Data are arranged in descending order 
according to AK levels. Data are represented as mean *p < 0.05; **p < 0.01; ***p < 0.001; 
(Dunnett’s test). IGF1R (Insulin Growth Factor 1 Receptor). mTOR (Mammalian Target of Rapamycin) and PI3k 
(Phosphoinositide 3-Kinase). 
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Figure S1.
A
B
Supplementary Figure 1. Valida on of ATP assay. A, Correla on of cell density and rela ve luminescence using ATP 
assay. Neonatal rat cardiomyocytes were plated onto 96-well plate at the density of 20 000 to 60 000 cells per well. 
72 h a er pla ng, cells were lysed, and ATP levels were measured. Shown are linear regression and Pearson's 
correla on coeﬃcient between ATP levels and number of cells plated. B, Correla on of cardiomyocyte protein 
content and cellular ATP levels. Neonatal rat cardiomyocytes were plated at diﬀerent cell densi es. 24 h a er 
pla ng, Cells were lysed with 0.1 M NaOH or ATP assay lysis reagent for determina on of protein or ATP content 
respec vely. Shown are linear regression and Pearson's correla on coeﬃcient between ATP levels and protein 
content.
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Supplementary Figure 2. Cardiomyocyte toxicity of selec ve inhibi on of PI3K, IGF1R, mTOR and PI3K/mTOR. Neonatal rat 
cardiomyocytes were treated with 4 diﬀerent concentra ons of each inhibitor for 24 hours. Concentra ons from le  to right 
are 0.1, 1.0, 3.0, and 10 µM. At the end of experiment, medium samples were collected for adenylate kinase (AK) assay (right 
panels) and cells were lysed for measurement of ATP levels (le  panels). Data from ATP assay is shown as percent of viable 
cells and AK assay as fold change in AK release vs control (DMSO). IGF1R (Insulin Growth Factor 1 Receptor), mTOR 
(Mammalian Target of Rapamycin) and PI3K (Phosphoinosi de 3-Kinase). Data are presented as mean±SD *p < 0.05; **p < 
0.01; ***p < 0.001; (Dunne 's test).
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Figure S3.
Supplementary ﬁgure 3. qPCR analysis of PI3Kα, IGF1R and RICTOR mRNA levels.Neonatal rat 
cardiomyocytes were transfected with 70 nM siRNAs targeting PI3Kα, IGF1R or  RICTOR.
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